Kite

© GettyImages/Design Cells

Milestone approval for Kite CAR-T cell therapy

By Jane Byrne

The US FDA has approved Yescarta, Kite's CAR-T cell therapy, for initial treatment in adults with large B-cell lymphoma (LBCL) that is refractory to one prior therapy or that relapses within 12 months of first-line chemoimmunotherapy.

(Image: Getty/Rawpixel)

Hired and Retired: A summer of change

By Vassia Barba

As we have entered the summer, companies have taken to refreshing their leadership positions, including at companies such as Gilead, Alnylam, and Maze Therapeutics.

(Image: Getty/NicoElNino)

Yescarta to Europe: Steps learned and production 97% on-spec

By Ben Hargreaves

The difficulties in the manufacture of CAR-T treatments have become increasingly understood as the breakthrough technology has been commercialised, but Kite’s head of medical affairs says its process is nearly flawless.